Hence, we used the DEN-induced cirrhotic rat model of HCC that reproduces key features of human HCC [17] to attest the safety and prove the efficacy of AKT inhibitor vevorisertib as a single treatment and in combination with sorafenib. The gene discussed is AKT1; the disease is hepatocellular carcinoma.